LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that CUBICIN® (daptomycin for injection) is now approved for marketing in Canada. The approval was granted on Monday by Health Canada. Oryx Pharmaceuticals, Inc. (Oryx) has licensed CUBICIN for the Canadian market from Cubist. The approved label includes both complicated skin and skin structure infections caused by certain Gram positive infections, at an approved dose of 4 mg/kg, and bloodstream infections, including right-sided infective endocarditis, caused by Staphylococcus aureus, at an approved dose of 6 mg/kg.
